News
![Does pharma’s future lie in China](https://pharmaphorum.com/wp-content/uploads/2020/03/Does-pharmas-future-lie-in-China.jpg)
AZ, HutchMed's savolitinib gets 1st approval in China for NS...
AstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a treatment of patients with a form of non-small cell lung cancer.